HAV is a positive stranded nonenveloped RNA virus that is transmitted via the fecal-oral route (Martin and Lemon, 2006; Traore et al., 2012). It is the most common cause of acute viral hepatitis globally (Hauri et al., 2006). It does not cause chronic hepatitis but it adds to further deterioration of liver infected with other hepatotropic viruses (Keeffe, 1995; Vento et al., 1998). A vaccine is available against it (Hauri et al., 2006). No specific treatment is available against it but the disease is self-limiting and there is no lasting injury.

HBV is transmitted through exposure to contaminated blood products and body fluids (Myers et al., 2002). It is a DNA virus. Chronic infection with hepatitis B virus (HBV) is estimated to affect 400 million individuals globally, and it is the leading cause of HCC (Lok et al., 2001). Vaccines and antiviral therapies are available against HBV (Das et al., 2019; Zhu et al., 2022).

HCV is transmitted through exposure to contaminated blood products (Myers et al., 2002). HCV affects more than 170 million people worldwide (Bhatia et al., 2014; Manns et al., 2017). Coinfections of hepatitis viruses are frequently observed in clinical setting. Furthermore, their propensity for chronicity sets the stage for superinfection with other viruses (Myers et al., 2002). It frequently causes chronic infection, leading to hepatocellular carcinoma (HCC; Vento et al., 1998; Manns et al., 2017). No vaccine is available against it. Treatment options for HCV cases include a combination of broadly-acting antivirals (such as peg-interferon, ribavirin) and specific direct-acting antiviral (Sofosbuvir; Bhatia et al., 2014).

HDV is transmitted through exposure to contaminated blood products and body fluids (Myers et al., 2002). It requires the HBV surface antigen (HBsAg) to replicate and is dependent on the latter (Huang and Lo, 2014). Around 5% of HBV carriers (approximately 20 million individuals) are coinfected with the HDV (Myers et al., 2002). No vaccine is available against HDV but HBV vaccinated people are protected from it as it is a significant threat only in HBV infected individuals. Recently, Bulevirtide was shown to be a potential treatment option against HDV (Dietz-Fricke et al., 2023).

HEV is a positive stranded quasi-enveloped RNA virus (Nimgaonkar et al., 2018). It is transmitted via the fecal-oral route. It can also get transmitted via blood transfusion. Zoonotic transmission of HEV from animals to human is also reported. It is a major cause of acute viral hepatitis globally (Primadharsini et al., 2021). HAV and HEV are major cause of community level outbreaks and epidemics in areas with poor sanitary conditions (Wu et al., 2016; Primadharsini et al., 2021). It may cause chronic infection in immune compromised individuals. At present, a vaccine against HEV is available in China (Wu et al., 2016). HEV cases are self-limiting in otherwise healthy individuals. A combination of broadly-acting antivirals are the option for off-label therapy in severe HEV cases (Netzler et al., 2019).

There is a need to formulate more potent, side-effect free therapeutics for treatment of viral hepatitis cases (Cowan et al., 2011). Controlled zinc supplementation is known to be a safe, side effect free therapy against Wilson’s disease (Brewer et al., 2000). Zinc is widely used as an antimicrobial agent, without any side effect (Wessels et al., 2022). Zinc supplementation is a part of standard care in the treatment of diarrhea in infants (Bajait and Thawani, 2011). Multiple laboratories have independently evaluated the antiviral potential of zinc against hepatitis viruses using diverse experimental approaches. Compilation and careful interpretation of the available data will be useful in evaluating the therapeutic potential of zinc in the treatment of viral hepatitis cases. Below sections compile majority of the available data on antiviral activity of zinc in vivo and in vitro.

Multiple clinical trials have been performed to determine the therapeutic benefit of zinc supplementation in viral hepatitis patients (Table 1). Majority of the trials involved HCV patients (10 trials), one trial involved HBV patients and one trial involved HEV patients. In some studies, serum zinc level was measured in the patients before and after the treatment regimen and compared to that of the placebo group. Pre-existing zinc deficiency was observed in 4 trials while normal zinc level was observed in 3 trials and zinc level was not measured in 5 trials. Zinc supplementation increased the serum zinc level in three of the four zinc deficient groups tested. Effect of zinc supplementation on disease outcome was evaluated by measuring the levels of serum albumin, ALT (alanine aminotransferase), AST (aspartate aminotransferase) and viral load [sustained viral response (SVR)]. In trials involving only zinc supplementation or zinc supplementation in addition to the standard antiviral therapeutics, there was an increased therapeutic response, compared to the placebo group. However, there was lack of positive clinical outcome with Zinc supplementation in four trials of chronic HCV cases (Table 1). In summary, these studies support the therapeutic benefit of zinc supplementation in a subset of viral hepatitis patients.

Serum zinc levels are decreased in HCV patients and the underlying mechanism is proposed to be due to the requirement of zinc binding by the viral non-structural proteins NS3 and NS5A (Love et al., 1996; Stempniak et al., 1997; Tellinghuisen et al., 2004). Comparison of serum zinc levels in chronic hepatitis C patients before and after treatment with Direct acting antivirals (DAAs) revealed an increase in the serum zinc level after DAA treatment (Suda et al., 2019). Importantly, they showed that the increased zinc level was not attributed to an increase in the albumin level, but it was a direct outcome of the viral RNA clearance (Suda et al., 2019).

Chronic hepatitis due to HCV infection is a known risk factor of HCC. In an interesting study, Hosui et al. evaluated the effect of oral zinc supplementation on the risk of HCC development in DAA treatment-cured chronic hepatitis C suffering individuals (Hosui et al., 2021). One year and three year follow up study after the end of DAA therapy showed cumulative incidence rates of 1.8 and 5.6%, respectively in the no zinc supplemented (control) group. None from the zinc supplemented group developed HCC. Moreover, serum zinc concentration was significantly higher in the no HCC group than the HCC group (Hosui et al., 2021). These data suggest the therapeutic benefit of zinc supplementation in reducing the risk of HCC development in individuals recovered from chronic hepatitis C.

In addition to viral infections, there are other inducers of hepatic dysfunction such as alcohol consumption. Multiple independent clinical trials have been carried out to assess the therapeutic benefit of zinc supplementation in non-viral hepatitis patients with liver cirrhosis (Overbeck et al., 2008; Diglio et al., 2020). Zinc supplementation significantly increased the serum zinc level, reduced the serum albumin level and improved the overall disease condition in those patients, further attesting the therapeutic benefit of zinc in hepatitis patients (Overbeck et al., 2008; Diglio et al., 2020).

Several independent studies support the antiviral role of zinc on replication and survival of HAV, HCV and HEV (Table 2; Figure 1). All studies used safe dose of zinc, which did not affect the viability of the cells that were used in the experiment. Zinc sulphate partially inhibited the replication of HAV in Huh7 (human hepatoma) cells (Ogawa et al., 2019). Zinc sulphate and zinc chloride inhibit replication of the genomic length HCV RNA at a concentration of 100 μM, with maximum effect at 48 h of treatment (Yuasa et al., 2006). Another study by Gupta et al. compared the HCV inhibitory effect of zinc oxide nanoparticles [ZnO(NP)] and tetrapods [ZnO(TP)] with conventional zinc salts such as ZnSO₄, which revealed the superior antiviral potency of the ZnO(TP) against HCV (Gupta et al., 2022). Zinc salts, ZnO(NP) and ZnO(TP) also show antiviral activity against HEV, latter being the most potent (Gupta et al., 2022). ZnO(NP) and ZnO(TP) are nanoparticle conjugated variants of ZnO, which is better absorbed in the intestine, possess better bioavailability and reduced undesirable side effect characteristics (Sirelkhatim et al., 2015; Jiang et al., 2018). Therefore, ZnO(NP) and ZnO(TP) are safer alternatives to the conventional zinc salts for therapeutic use. Inhibitory effect of ZnO(TP) was comparable to that of sofosbuvir, a well-known DAA used in the treatment of HCV cases, further testifying the antiviral potential of ZnO(TP) against HCV (Yuasa et al., 2006; Gupta et al., 2022).

Zinc may directly accumulate on the virus and inactivate it or interfere with its entry into the target cell. Zinc application leads to its deposition on HSV thereby inactivating the virus and inhibiting its cellular entry (Kümel et al., 1990). Recently zinc Oxide tetrapod nanoparticles with engineered oxygen vacancies (Zoten) were shown to possess potent therapeutic benefit in HSV-2 (Herpes simplex virus-2) mediated genital herpes (Antoine et al., 2016). Zoten blocks cellular entry of HSV-2 by efficiently trapping and inactivating the virus, thereby preventing the disease (Figure 2). It also enhances T cell and antibody mediated immunity in mice, have adjuvant like properties and thus reduces chances of reinfection (Antoine et al., 2016; Samad et al., 2021). Zinc treatment was shown to moderately inhibit enterovirus D68 attachment and entry into target cells (Figure 3; Liu et al., 2021). In the case of Rhinovirus, zinc may act as a competitive inhibitor of virus binding to the ICAM1 (intercellular adhesion molecule 1) on the host cell surface, which is the receptor for virus entry (Hulisz, 2004; Figure 3). Zinc and Nickel inhibit membrane fusion of SFV (Semliki forest virus) by targeting the viral transmembrane E1 protein (Figure 3; Liu and Kielian, 2012).

Zinc inhibits proteolytic processing of nonstructural polyproteins of several viruses such as rhinovirus and Picornavirus (Krenn et al., 2009). Zinc ionophores such as Pyrithione and Hinokitol also demonstrate antiviral activity by inhibiting the processing of picornavirus nonstructural polyprotein (Krenn et al., 2009). Zinc treatment inhibits HSV-2, Sindbis, FMDV (Foot and mouth disease virus) and Vaccinia virus growth in infected cells by blocking their polypeptide processing (Figures 2, 3; Bracha and Schlesinger, 1976; Gupta and Rapp, 1976; Polatnick and Bachrach, 1978; Katz and Margalith, 1981).

Replication of viral genome is an essential step for proliferation and maintenance of genomic integrity of the virus. RNA dependent RNA polymerase (RdRp) produced by proteolytic processing of the viral nonstructural proteins plays the central role in the viral replication process. Zinc inhibits RdRp activity of many viruses, including TGEV (Transmissible gastroenteritis virus), SARS-CoV (Severe acute respiratory syndrome coronavirus), EAV (Equine arteritis virus), Rhinovirus and HEV (Hepatitis E virus; Korant et al., 1974; Hung et al., 2002; Te Velthuis et al., 2010; Wei et al., 2012; Kaushik et al., 2017). Different steps in the replication process have been shown to be targeted by zinc for inhibiting RdRp activity. In case of SARS-CoV, zinc treatment reduced template binding and elongation by the RdRp whereas in case of EAV, initiation step of RNA synthesis was inhibited (Te Velthuis et al., 2010). Zinc also inhibits Rhinovirus RdRp activity in vitro although the mechanism remains to be understood (Korant et al., 1974; Hung et al., 2002). Clinical trials have shown the therapeutic benefit of zinc in alleviating rhinovirus induced common cold symptoms (Eby et al., 1984; Hulisz, 2004; Kurugöl et al., 2006). Zinc inhibits HIV-1 (Human immunodeficiency virus-1) protease and reverse transcriptase activity (Zhang et al., 1991; Haraguchi et al., 1999; Fenstermacher and DeStefano, 2011). Some other HIV-1 encoded proteins are dependent on zinc to carry out their function (Zheng et al., 1996). Effect of zinc supplementation in HIV infected patients have been investigated in clinical trials (Mocchegiani and Muzzioli, 2000; Bobat et al., 2005; Baum et al., 2010). HIV infected children showed a significant decrease in the frequency of watery diarrhea after 3 months of zinc supplementation. However, neither viral load was altered nor CD4⁺ T lymphocytes level was improved (Bobat et al., 2005). Similar effect of zinc supplementation was observed in HIV infected patients having pneumocystis carinii and candida (Mocchegiani et al., 1995). Another study has shown potent antiviral activity of PEGylated ZnO nanoparticle against H1N1 influenza virus (Ghaffari et al., 2019). Recently, polyamide fibers with embedded zinc ions (zinc oxide) were shown to prevent and deactivate Influenza A virus H1N1 and SARS-CoV-2 (Gopal et al., 2021). Further, higher zinc intake was found to reduce the severity of disease in COVID-19 patients (Asoudeh et al., 2023). In addition, many clinical trials have attempted to evaluate the therapeutic benefit of zinc in COVID-19 patients (Carlucci et al., 2020; Chinni et al., 2021; Gordon and Hardigan, 2021; Thomas et al., 2021; Beran et al., 2022; Tabatabaeizadeh, 2022). Though some studies reported a positive outcome, further investigation is warranted to draw a clear conclusion.

Zinc is also reported to act by inhibiting viral particle production and inhibit viral topoisomerase activity in vaccinia virus, inhibit endosomal membrane fusion in Semliki Forest virus and inhibit viral protein E6 and E7 synthesis (thereby stimulating apoptosis) in Human papilloma virus infected cells (Read et al., 2019).

Metallothionein (MT) is a cysteine rich low molecular weight protein, which binds to zinc and copper to regulate their homeostasis in cells and also sequester heavy metals such as cadmium and mercury to alleviate heavy metal poisoning and superoxide stress. There are four MT isoforms in mice (MT1-4) and several isoform/variants in human (Vašák, 2005). MT1 and MT2 are expressed in all organs, while MT3 is expressed in brain and MT4 in stratified tissues. About 10% of human genome encode zinc binding proteins which play crucial biological functions. The availability of zinc is regulated by MT and zinc transporters. MTs sense the intracellular zinc level and modulate zinc through sequestration, distribution and release. Promoter region for MT1 and MT2 contains several metal and glucocorticoid regulatory elements (MREs and GREs). Metal responsive transcription factor 1 (MTF-1) regulates the transcription of MTs (Figure 4; Vašák, 2005). MTF-1 contains six zinc fingers which is responsible for DNA binding, and thus binds to the promoter proximal MREs. Increased Zinc concentration mediate efficient DNA binding of MTF1 (Grzywacz et al., 2015). Another study has shown that during cellular stress, Nitric Oxide (NO) produced by immune cells induce MT1 and MT2 to release zinc and these free zinc ions bind to MTF1, leading to its activation (Stitt et al., 2006). MTs mobilize zinc to nucleus, cytoplasm, golgi and endoplasmic reticulum. MTs also interact with proteins such as GTP, ATP, Gluthatione and these interactions enable their localization in extracellular milieu (Maret, 1994; Jiang et al., 1998; Subramanian Vignesh and Deepe, 2017).

It has been postulated that MTs deliver zinc to the thymulin, which is important for the function of the latter and that aberrant MT regulation can have direct effect on downstream functions of thymulin such as T cell selection, differentiation and function (Subramanian Vignesh and Deepe, 2017). Zinc also regulates the expression of MHC II on dendritic cell (DC) surface. Excess zinc reduces MHC II expression while zinc deficiency elevates MHC II expression on DCs. Thus, it has been proposed that MT-Zn sequestration regulates MHC II expression in DCs, further influencing thymic T cell selection (Kitamura et al., 2006; George et al., 2016).

Several studies also suggest that MT-Zn homeostasis regulates immunological function of bone marrow. Reports have shown that either deficiency of dietary zinc and chronic zinc exposure leads to B-cell and T-cell apoptosis (King et al., 1995; Fraker and King, 2004). Thus, absence of MT expression in bone marrow diminishes zinc homeostasis unless compensatory zinc transporters and MTs are provided. MTs transfer zinc to other metalloproteins including the zinc-dependent transcription factor which regulates the differentiation of precursor cells in bone marrow. For example, Early growth response-1 (Egr-1), a zinc-dependent transcription factor promotes differentiation of monocyte into macrophage (Krishnaraju et al., 1995), while another zinc dependent transcription factor growth factor independent-1 (Gif-1) antagonizes monocyte to macrophage differentiation and rather promotes neutrophil differentiation (Hock et al., 2003). Studies have also shown that exogenously added Zn-MT binds to unknown MT receptor on T-Cell membrane and reduces surface thiol expression. This enhances IL-2 release which promotes T-Cell survival and proliferation (Subramanian Vignesh and Deepe Jr., 2017).

Dendritic cells express MTs in response to thermal stress, which then mediate zinc distribution to regulate intracellular redox environment in DCs. MT1 expressed in DCs induces tolerogenic potential of DCs by promoting differentiation of naïve T cell into FOXP3 expressing Treg cells (Reis e Sousa, 2006; Maldonado and von Andrian, 2010). During inflammation and changed redox state of cells, MTs release zinc. These free zinc ions activate MTs, stimulate MTF-1 and downregulates pro-inflammatory cytokines such as IL6, TNF-α, interleukin IL-1 and also suppresses transcription factor NF-kB. NF-kB induces the expression of pro-inflammatory cytokines 1 L-1, IL-6, TNF- α, which activates MTF-1 transcription factor. MTF-1 upregulates the expression of MTs, and zinc efflux transporter ZnT-1, which helps in maintaining Zn-MT homeostasis and helps recover cells from redox state (Figure 4; Grzywacz et al., 2015).

Zinc transporters play important roles in Zn²⁺ transport, distribution and homeostasis (Lazarczyk and Favre, 2008; Lichten and Cousins, 2009). Zinc transporters belong to two families: 10 SLC30s/ZnTs and 14 SLC39s/ZIPs. ZIPs mediate influx of Zn²⁺ from extracellular space to intracellular cytoplasm via diffusion, symporter or secondary active transporter. ZnTs export Zn²⁺ from cytoplasmic space to extracellular space (Andrews et al., 2004; Lichten and Cousins, 2009). The ZnTs and the ZIPs with their expression and distribution in the different tissues are listed in the Table 3. Inside the cell, specific set of ZnTs and ZIPs are involved in storage of Zn²⁺ in organelles or its release into cytosol, depending on the state of the cell. Intracellular distribution of ZnTs and ZIPs is schematically shown in Figure 5.

Through sequence analysis it was observed that the ZIP family of transporters contains 8 transmembrane domains (TMDs-1-8). These 8 transmembrane domains are responsible for the zinc transport. A cytoplasmic segment lies between the 3^rd and 4^th TMD (Taylor and Nicholson, 2003; Bin et al., 2011). These proteins are further divided into four subfamilies- I, II, gufA, and LIV-1 (Taylor and Nicholson, 2003). Amongst these, the LIV-1 sub family members contain a HEXXH motif within TM5 (transmembrane domain 5) and varying lengths of the N-terminal extracellular domain (ECD; Taylor and Nicholson, 2003). Out of the 14 ZIPs identified in mammals, ZIP1, ZIP2, ZIP3 belong to the ZIP II subfamily. ZIP 9 is a member of the ZIP I subfamily and ZIP 11 is of the gufA subfamily (Yu et al., 2013). The remaining 9 ZIPs belong to LIV-1 subfamily (Ryu et al., 2020). The functional roles of LIV-1 subfamily proteins are predominantly due to their ECDs. The role of the ZIP-CTD present between TM3 and TM4 remains unknown (Bin et al., 2018).

The transport mechanisms being used by ZIPs is not yet clearly elucidated and requires further study, but the cell-based assays done using isotopes suggest that ZIP2 controls the zinc flux through a time, temperature and concentration dependent manner as seen in erythroleukemia cells (Gaither and Eide, 2000). It was further seen that ZIP2 was stimulated only by HCO₃-, with a high affinity to zinc, suggesting a Zinc- HCO₃- symporter mechanism (Gaither and Eide, 2000). ZIP8 has also been shown to act as a Zn- HCO₃⁻ symporter in complementary RNA injected Xenopus oocytes (Liu et al., 2008).

ZnTs are part of a superfamily of cation diffusion facilitators. Mammalian ZnTs are predicted to have at least 6 TMDs (Fukada and Kambe, 2011). The ZnTs possess a histidine/serine rich loop of differing lengths between the 4th and 5th TMDs (Fukada and Kambe, 2011). Further ZnTs contain a large cytoplasmic domain at the C- terminus (CTD) with a copper chaperone like architecture (Lu and Fu, 2007). This domain has an important role in diabetes research as mutations in the CTD of ZnT8 increases the risk of developing diabetes (Parsons et al., 2018). The transport mechanism utilized by ZnTs is not clearly understood in the mammalian system, but studies done on E. coli Zinc transporter YiiP suggests that ZnTs control the zinc efflux through a Zn²⁺/H⁺ antiporter (Lu and Fu, 2007).

Zinc is an essential component of several cellular processes in the host. It is also essential for normal development and functioning of the innate and adaptive immune systems. The diverse functional properties help in further strengthening the antiviral action of zinc, either by stimulating a better immune response in the host and/or by promoting the synthesis/activation of antiviral factors/pathways, as described in the following sections.

Zinc homeostasis in the cell is a multistep process constituting three main stages, namely the zinc influx into the cells, zinc efflux from the cells and the storage within the cells. As described earlier, this process is realized through zinc transporters and the zinc binding proteins. In normal conditions, zinc homeostasis is tightly and neatly controlled, but while considering zinc supplementation, the dosage and the amount need to be judiciously and carefully curated. Any imbalance of zinc levels due to supplementation might cause disruption of zinc transport, leading to zinc accumulation in the cells causing toxicity. One of the major challenges to zinc supplementation is that zinc is needed in a large number of cellular processes and therefore interacts with a large number of proteins. It is really difficult to keep track of the effect of zinc supplementation on all these proteins.

A number of reports suggest that differential expression and activity of ZIP and ZnTs are responsible for the pathogenesis and progression of chronic diseases. ZIP transporters are known to promote the invasive activity of cancers. Reduced expression in ZIPs has been seen in prostate cancer, where the cellular zinc is reduced, which accelerates the disease progression. ZIP4 is known to get atypically overexpressed in case of “acrodermatitis enteropathica.” ZIPs are known to play roles in epithelial–mesenchymal transition, anoikis resistance, and metastasis. In such cases, abnormal expression of ZIPs elevates the cytosolic zinc levels, which may extend the zinc dependent growth factor signaling and cause aberrant activation of cellular signaling pathways (Kagara et al., 2007). A myriad of secretory and membrane-bound enzymes which need zinc like matrix metalloproteinases are involved in cancer metastasis, and capture zinc in the early secretory pathway. Thus, ZnT transporters like ZnT5, ZnT6, and ZnT7 might be facilitating zinc uptake by these enzymes and their activation (Kambe, 2012). These examples merely illustrate that abnormal dysregulation of the zinc transporters have been observed in various disease and zinc supplementation could have a similar effect on these transporters and could lead to deleterious effects if not administered correctly.

Zinc interferes with the copper absorption in the body, even at a very little dose above the RDA (Recommended Dietary Allowance). Actually, higher concentration of zinc induces more expression of metallothioneins in the lumen to absorb more amount of zinc. However, this protein also has a high affinity for copper, resulting in a copper deficiency, and may cause anemia, neutropenia and myelopathy (Francis et al., 2022).

Zinc is known to have many beneficial functions and has seen to play a role in protection in various infectious diseases, but excess zinc can cause zinc toxicity or side effects. Most often the zinc toxicity depends on the route of exposure to zinc or on the dosage. Zinc toxicity can be divided into two types- (a) acute and (b) chronic toxicity. Acute toxicity is caused by ingestion of salts of zinc such as zinc sulphate and zinc chloride which manifests into gastrointestinal symptoms like diarrhea, renal injury, acute respiratory distress syndrome (ARDS), liver necrosis, thrombocytopenia, coagulopathy and might lead to death in extreme cases (Barceloux, 1999). Chronic toxicity causes bone marrow damage and neurological symptoms. One of the major causes of concern in case of chronic toxicity is that if zinc is chronically ingested it can result in copper deficiency can lead to sideroblastic anemia, granulocytopenia, and myelodysplastic syndrome (Irving et al., 2003; Sheqwara and Alkhatib, 2013). Orally consumed zinc is absorbed by the jejunum of the small intestine. This process is facilitated by the metallothionein complex in the enterocyte villi (Ruttkay-Nedecky et al., 2013). Zinc binds to the metallothionine, which is known to be involved in the regulation of other metals as well, especially copper having the highest affinity to it (Ruttkay-Nedecky et al., 2013). To remove the excess zinc, the human body produces more metallothionein to prevent excess free zinc but in turn also decreases copper levels, thus, forming a dynamic antagonistic relationship. Here, the zinc homeostasis can only be maintained by the excretion of the metallothionein-zinc complex via bile and faeces. In case of zinc overdose, excretion of zinc will not be fast enough and thus it will get accumulated and cause clinical complications (Agnew and Slesinger, 2020).

Due to the advancement in nanotechnology, biomedical nanoparticles have gained considerable attention due to their prominence in biomedical applications and are being explored for molecular diagnostics, drug delivery, gene therapy. In case of Zinc based nanotechnology, zinc oxide-based nanoparticles have taken the center stage (Zhang and Xiong, 2015; Bashandy et al., 2018).

Zinc oxide nanoparticles (ZnO NPs) are important and are used in a variety of fields due to their unusual properties. ZnO nanoparticles have a small particle size which helps in the easier absorption of zinc by the body and are used as food additives and the US FDA has classified it as a GRAS (Jiang et al., 2018). In addition to this ZnO NPs are relatively inexpensive and less toxic. These properties make ZnOs an excellent candidate for biomedical applications. ZnOs have been used in anti-cancer treatment, drug delivery, antibacterial, diabetes treatment, anti-inflammation, wound healing and bioimaging (Zhang and Xiong, 2015; Mishra et al., 2017). In recent years nanoparticles of gold and silver have been predominantly studied and deployed against viral diseases. However, Zn nanoparticles might be relatively less toxic than silver and gold nanoparticles and more cost efficient. ZnO nanoparticles have proven to be successful as a therapeutic strategy for various viral diseases, although they have not been very extensively studied in animal as well as human models, but promising results have been obtained in various cell-based models (Aderibigbe, 2017). Zinc oxide nanoparticles have been shown to have a virostatic effect against HSV-1 and were able to efficiently trap virions from entering the human corneal fibroblasts (Mishra et al., 2011). Surface modified zinc oxide nanoparticles have been shown to alter the infection of Herpes simplex virus -I by neutralizing the virus by utilizing the electrostatic interference caused by the hydrophobic zinc nanoparticles (Farouk and Shebl, 2018). PEGylated zinc oxide nanoparticles have been shown to be successful in inhibiting H1N1 viral infection and there was a 1.2 log10 TCID50 decrease in the viral titer (Ghaffari et al., 2019). Further ZnO nanoparticles suppressed replication in case of nidovirus and also have been shown to disrupt the replication of a range of RNA viruses (Gurunathan et al., 2020). In MA104 cells (African green monkey fetal kidney), ZnO nanoparticles led to a 10-fold decrease in the chikungunya viral load (Kumar et al., 2018).

In addition to this, ZnO tetrapods have also been used as an alternative for the traditional nanoparticles (Mishra and Adelung, 2018). The unique 3D structure gives them a higher flexibility as a biomedical engineering tool than traditional spherical or 1D nanoparticles as tetrapods avoid the agglomeration issues faced by the other two. The first use of ZnO nano tetrapods was for the efficient delivery of plasmid DNA (Nie et al., 2006). Furthermore, zinc tetrapods have been used to trap virus particles using oxygen vacancies on the synthesized ZnO tetrapods. Polar surfaces were created in the tetrapods due to the oxide, which helped in trapping the negatively charged functional glycoprotein groups present on the virion surface (Mishra et al., 2011). Dendritic cells could easily take up such entrapped virus particles and neutralize them. This success of this strategy has been shown in humans and mice in the cases of HPV, ZIKA, HIV and Dengue. Apart from this ZnO nanoparticles and tetrapods have been shown to have an antiviral role in HSV, HEV and HCV by suppressing the viral replication (Mishra et al., 2011; Gupta et al., 2022).

Although zinc based nanoparticles have been shown to play antiviral roles they need to be further characterized to be successfully established as a commercially available therapeutic for viral diseases.

Zinc transport can be modulated by zinc ionophores. Zinc ionophores have been shown to inhibit replication of many viruses in vitro. Four zinc ionophores have shown to have antiviral roles which are Pyrithione, Hinokitiol, PDTC and Chloroquine. Pyrithione, Hinokitiol and PDTC inhibit the replication of the following viruses in vitro: coxsackievirus, equine arteritis virus, SARS-CoV, HSV, mengovirus and rhinovirus (Lanke et al., 2007; Krenn et al., 2009; Te Velthuis et al., 2010; Qiu et al., 2013). Chloroquine inhibits the replication of the following viruses: HCV, HCoV-229E, MERS-CoV, SARS-CoV, HIV-1 and Zika virus (Romanelli et al., 2004; Delvecchio et al., 2016; Read et al., 2017; Chandru et al., 2018). In addition to this, another zinc ionophore, Quercetin is known to inhibit replication of Influenza A virus and Rhino virus (Wu et al., 2016; Mehrbod et al., 2021). These studies indicate that zinc ionophores may be used as antivirals and since zinc has a significant role to play in liver homeostasis, the use of these ionophores is likely be an excellent antiviral strategy against hepatitis causing viruses.

ZnO NPs have shown promise in biomedical applications due to their anti-viral, anti-bacterial and anti-diabetic roles. Inherently toxic, the ZnO NPs inhibit cancerous cells as well as bacteria by generating intracellular ROS generation. This activates the apoptotic signaling pathway making these nanoparticles excellent anticancer and anti-bacterial agents. Furthermore, Zinc nanoparticles and tetrapods have shown significant antiviral activities ranging from affecting replication, to neutralizing viruses and influencing viral entry. As drug carriers, ZnO NPs enhance therapeutic efficiency by promoting the bioavailability of the drugs or biomolecules.

The FDA has listed ZnO NPs as a safe substance. However, they should be further explored and studied as there are no comparative analysis of the biological advantages of Zinc nanoparticles over other metal nanoparticles. Further, there is lack of information on evidence based randomized trials and animal studies emphasizing their therapeutic roles. Focused studies on these aspects would help us better understand their diagnostic and therapeutic potential.

It is also important to be cautious and careful while interpreting and extrapolating the data obtained from cell-based experiments to patient studies. Generally zinc compounds are used in micromolar (μM)-millimolar (mM) concentration in the cell-based studies to evaluate their antiviral potential whereas plasma zinc concentration ranges between 10 and 18 μM in human (Rükgauer et al., 1997). On top of that free zinc levels are very tightly controlled in vivo. Although intracellular level of zinc maybe in micromolar concentration, most of it is bound to metallothioneins, thereby reducing the free zinc concentration to nanomolar scale (Krężel and Maret, 2006; Zheng et al., 2017). Such complex regulation makes it difficult to fully harness the therapeutic benefit of zinc based on the data obtained in cell-based experiments. Therefore, even though a zinc compound may exhibit very potent antiviral effect in laboratory condition, it needs stringent evaluation in the clinic.

The treatment of viral hepatitis has evolved rapidly over the last few years especially with the introduction of curated therapies for Hepatitis C. In addition to this the improvement in HAV, HBV and HEV vaccination has also led to a significant advance in viral hepatitis management. Viral hepatitis treatment is still dependent on a few drugs like Ribavirin and PEGylated Interferon but none of these are known to specifically target these viruses. Thus, targeted therapies can be further explored; one such strategy could be the use of zinc salt, zinc nanoparticles and zinc ionophore based therapies. We have recently shown the antiviral activity of zinc oxide nanoparticles and tetrapods against HEV and HCV, which could pave the way for the development of new therapeutic strategies against these viruses (Gupta et al., 2022).

Zinc oxide nanoparticles have shown promising antiviral effects on various viruses, but further research needs to be performed to explore and understand the underlying mechanism of zinc nanoparticles dependent antiviral activities. Zinc seems to inhibit the enzyme activities of viral protease and polymerases and is also involved in the physical processes of viral attachment and uncoating (Mishra et al., 2011). However, it is important to study these in clinical scenarios as zinc could become a viable supplement to the traditional viral treatments. A number of in vitro studies have demonstrated that free zinc possesses a strong antiviral effect through the trials with creams and tablets containing higher amounts of zinc (Mishra et al., 2011). These studies also tell us that when zinc is used at therapeutic doses and in the right form could improve viral clearance in case of acute and chronic infections. Zinc supplementation can be successful in two ways: it can be either be administered to improve the systemic immunity and the antiviral response in zinc deficient patients or can be used to specifically target viral replication and the symptoms of infection (Mishra et al., 2011). Although zinc-based strategies have been shown to have various roles in inhibiting the viral replication, there is a lack of information on whether these zinc-based strategies are sufficient as a standalone treatment or in enhancement of the effect of other antiviral treatments. Zinc supplementation with Ribavirin or PEGylated IFN-α reduced the side effects of Ribavirin/PEGylated IFN-α in case of HCV and HEV chronic patients but had no additive effect on these treatments (Farouk and Shebl, 2018; Suda et al., 2019). It has also been proven that in chronic patients of HCV and HBV zinc supplementation induces anti oxidative functioning of the liver preventing further liver damage during the treatment with Ribavirin and PEGylated IFN-α (Murakami et al., 2007). Zinc supplementation has also been shown to reduce inflammation and production of cytokines like NF-κB in chronic HCV and HBV patients (Nagamine et al., 2000). Accumulating data, through both in vitro and clinical studies, suggest that zinc supplementation in addition to other antiviral therapy is a viable treatment regimen for viral hepatitis. Although this needs to be further elucidated through large cohort based clinical studies.